Update on Atherosclerosis Treatment and Prevention
|
|
- Kory Ford
- 6 years ago
- Views:
Transcription
1 Update on Atherosclerosis Treatment and Prevention Ronald D. Scott, MD Lipidology and Family Medicine West LA Med Center Regional CVD Colead Overview Lipids and CAD risk CVD is major killer and impacts morbidity Large statin benefit opportunity Treat high LDL (> 190) regardless of risk. Treat those at risk, regardless of LDL (>70) Optimizing Performance Identifying patients STAtin: Starts, Titrations, and Adherence Use tools to promote statins Safety / intolerance of statins Beyond statins 1
2 Also, stroke is #3 cause of mortality and much feared, significant morbidity. Heart disease and stroke are very costly. Risk factor INTER-HEART: MI risk PAR adjusted for age, sex, and smoking (99% CI) Yusuf S. European Society of Cardiology Congress 2004 PAR adjusted for all (99% CI) ApoB/ApoA-1 (fifth 54.1 ( ) 49.2 ( ) quintile compared with first) Current smoking 36.4 ( ) 35.7 ( ) Diabetes 12.3 ( ) 9.9 ( ) Hypertension 23.4 ( ) 17.9 ( ) Abdominal obesity 33.7 ( ) 20.1 ( ) Psychosocial 28.8 ( ) 32.5 ( ) Vegetable and fruits 12.9 ( ) 13.7 ( ) daily Exercise 25.5 ( ) 12.2 ( ) Alcohol intake 13.9 ( ) 6.7 ( ) All combined 90.4 ( ) 90.4 ( ) 2
3 3
4 Last LDL > 190 in KPSC 33,000 KP So Cal members. If lifestyle not successful, statins recommended if age > 10 years old. Easy to tell in inbox if patient needs statin by this criteria. Is regardless of risk. For adults, lower LDL at least 50%. Start atorvastatin 80 mg daily (53% LDL lowering) Protective PCSK9 mutations Lifelong decreased levels of LDL. Variant 1: 28% reduced LDL 88% reduction in CAD. Variant 2: 15% reduced LDL 50% reduction in CAD. Event reduction impressive: favorable impact of low cholesterol over a long time 4
5 Risk in Primary Prevention Trials 10 y risk 5.0 % 7.5% 5
6 avg A-risk of 7.5 % Entry LDL<130, mean 105 avg FRS of 12% Entry LDL<130, mean 105 6
7 Large statin benefit +/- disease (including Primary Prevention) Primary prevention Lancet Nov 9, 2010 Statins benefit across age span - including those over age 75 CCT. Lancet Nov 9,
8 Statins benefit across range of baseline lipids Baseline LDL mg/dl < > 135 LDL 150 to 89 same benefit as LDL 77 to 45 Lancet Nov 9, 2010 HPS: NNT NNT (simvastatin 40 mg) to prevent one MI, stroke or revascularization in 5 years. DX NNT Post MI 10 Angina 12.5 s/p Stroke, PAD, DM age > Young DM with 80% Lifetime risk of CAD Simvastatin 40 mg in Heart Protection Study
9 JUPITER: NNT Statin risks, NNH NNH of new onset DM, myopathy. Conservative estimates. Harm not as severe as MI or stroke. Low to Moderate intensity statin (< atorvastatin 20 mg) 6 excess cases of adverse effects per 1000 statintreated persons over 5 years NNH = 167 High intensity statin (atorvastatin mg) 16 excess cases of adverse effects per 1000 statintreated persons over 5 years NNH = 63 9
10 Starting Statins Acute Ischemic Stroke / Acute Coronary Syndrome: atorvastatin 80 mg LDL > 190 (regardless of risk): atorvastatin 80 mg CAD / IVD, DM (age > 40 or RF), or FRS > 10%: atorvastatin 40 mg simvastatin 40 mg for cost sensitive members with higher atorvastatin copayments Consider lower doses, clinical judgment and / or shared decision making in patients with: baseline LDL < 70, Age > 76 years, Liver disease or muscle disorders. Asian ancestry. % on statin CAD/IVD. In last 6 mos 84% DM age > 40. In last 6 mos 76% LDL > 190. ever on statins 66% FRS > 10%. About 30% Need about 500,000 statin starts 10
11 Generic statins are cost saving in lower risk primary prevention High intensity statin over 10 years is cost saving vs low/moderate intensity statin with > 2.5% 10-year CVD risk Generic statins cost saving with > 5% 10- year CHD risk Pletcher MJ, et al. Ann Intern Med. 2009;150: ; Heart Protection Study Collaborative G. Circ Cardiovasc Qual Outcomes. 2009;2(2):65-72; Conly J, et al. Can Med Assoc J. 2011;183(16):E1180-E1188. FRS > 20% FRS 15% With revised guidelines, FRS>10% (and more) in statin target population. Large population with large treatment potential 11
12 STAtins - key to lipid control Start statins in the untreated Titrate up on the undertreated Adherence promotion / working barriers 12
13 Finding the inclusion code: IVD Ischemic Vascular Disease CAD: post MI, post CABG, post PCTA, angina. Status post stroke, carotid artery occlusion. Peripheral arterial disease, AAA. NOT include aortic atherosclerosis, aortic ectasia. 13
14 Abdominal Aorta Screening Abdominal Aortic Aneurysm (AAA) is considered CAD risk equivalent by NHLBI / ATP and KP guidelines statins and LDL < 100 control recommended. Is part of our CAD POINT registry for targeting. Aortic Screening Rate Trend 17% increase in region so far! 28 14
15 Diagnosis and Actions by Aortic Diameter < 2.4 cm: Normal diameter. (check for aortic athero) cm: Aortic Ectasia, place on problem list. Start statin if FRS > 10%. > 3.0 cm: Abdominal Aortic Aneurysm (AAA), start statin, code and place on problem list. > 4.0 cm: above actions, plus referral to vascular surgery. Aortic Ectasia cm Risk Hazard Ratio (crude) Acute MI 1.60 ( ) Stroke 1.59 ( ) Heart Failure 1.85 ( ) Total Mortality 1.46 ( ) Vascular Mortality 1.77 ( ) Duncan JL et al. BMJ 2012 May 4; 344:e
16 Aortic Atherosclerosis and Aortic Ectasia Although not automatic risk equivalents, are markers of increased risk. Imaging findings show risk to patient. Revenue for KP. Patients more likely to have annual appointments. Imaging results can be used as opportunity to promote cardiovascular health. Positive imaging findings communicated with patients leads to higher statin and aspirin use (OR 7.0) J Am Coll Cardiol Apr 2008 Available to members with data elements Start atorvastatin 40 mg daily Framingham risk score (FRS) calculator. Expanding availability. Will change to A-risk in
17 "Pre-statin" and latest FRS are calculated and shown above. FRS > 10 %: start atorvastatin 40 mg FRS > 15% (or on treatment > 10 %): start aspirin 81 mg daily at kp.org for members 17
18 Artery image in-person patient education. Tear-off pads or posters, English or Spanish, illiterate. Order from Health Education and use in exam rooms. to reduce cholesterol, heart attacks and strokes in sig Smart Rx - Lipids 18
19 Titration Titration Table lovastatin or pravastatin dose Treated LDL-C level Change to: <= 20 mg atorvastatin 40 mg <= 20 mg > 129 atorvastatin 80 mg 40 mg atorvastatin 40 mg 40 mg >119 atorvastatin 80 mg 80 mg atorvastatin 40 mg 80 mg >109 atorvastatin 80 mg simvastatin dose Treated LDL-C level Change to: <=10 mg atorvastatin 40 mg <=10 mg >129 atorvastatin 80 mg 20 mg atorvastatin 40 mg 20 mg >119 atorvastatin 80 mg 40 mg atorvastatin 40 mg 40 mg >109 atorvastatin 80 mg 80 mg >99 atorvastatin 80 mg atorvastatin dose Treated LDL-C level Change to: < = 10 mg atorvastatin 40 mg < = 10 mg >119 atorvastatin 80 mg 20 mg atorvastatin 40 mg 20 mg >109 atorvastatin 80 mg 40 mg >99 atorvastatin 80 mg 19
20 Encouraging Letter Safety, intolerance and barriers 20
21 Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study Lancet Nov 24, 2010 Increased baseline ALT increased statin benefit? GREACE study: rrr of recurrent cardiovascular event Elevated liver tests NAFLD: 68% Normal liver function: 39% Consistent with other studies that those with NAFLD and steatohepatitis are at higher CV risk and may benefit more from statins. The FDA statin labeling change 2/28/12 revised to remove the need for routine periodic monitoring of liver enzymes. 21
22 Rosuvastatin risk of new DM JUPITER rosuvastatin 20 mg daily: In those without RF for DM: 86 CV events prevented, and 0 cases of increased DM. In those with RF for DM: 134 CV events prevented (MI stroke, death) and 54 new cases of DM. (28% increase) 40 day acceleration of progression to DM. Compare to 55% reduced MI, 44% reduced combined endpoint, 20% lower mortality. DM risk drives NNH estimate of 63- Lancet 2012; 380: Atorvastatin risk of new DM Atorvastatin 80 mg overall OR 1.15 of New DM RF: FBS > 100, TG > 150, BMI > 30, HTN JACC, Jan Am J Car, Jan
23 statin muscle issues Risk Factors: interacting meds, statin dose relative to max, older age, female, cirrhosis... Check and treat high TSH (hypothyroid) before starting therapy. If muscle symptoms, double check if recent TSH. Consider treating low vitamin D. About 90% resolution of myopathy in 3 small studies. CoQ10, creatine,...? Muscle Risk lova simva prava rosuva atorva % LDL 20 mg 10 mg 20 mg % 40 mg 20 mg 40 mg mg 34% 80 mg 40 mg 80 mg 5 mg 20 mg 41% mg mg 40 mg 48% mg 80 mg 53% mg 58% Adapted from SLCO1B1 in Clin Pharm Ther. 2009;87(1):130-3 And FDA potency table 23
24 Muscle SE - options Low dose statin (relative to max) often with better tolerance. atorvastatin 10 mg daily 34% lowering. rosuvastatin 5 mg daily 41% lowering. If still not tolerating decrease frequency to 1-2 x a week atorvastatin or rosuvastatin most studied and long acting. If not tolerate multiple statins, red yeast rice? Red Yeast Rice has issues Arch Intern Med Oct
25 If non adherent, ask is cost a barrier? MFA program for patients that qualify. Mail order pharmacy incentive (3 months for cost of 2) Some Commercial Plans: Atorvastatin is not on KP CA Preventive Care Drug list, resulting in more copays and cost sharing than other generic statins. Medicare Senior Advantage Individual Plan patients make up 50% o our Medicare (age>65) patients. Tier 1 copay: $ 6 for 100 day supply with Mail Order. Simvastatin, lovastatin. Tier 2 copay: $ 14 for 100 day supply with Mail Order. Atorvastatin, pravastatin. Beyond Statins Priority is to optimize statin first, before going beyond statins to other lipid treatments. cost/yr % LDL atorvastatin 10 mg $ 34 % Red yeast rice $$ 17 % Add On Therapies ezetimibe 10 ½ tab $$$ (brand) 12 % Stanol Chews $$$ (OTC) 5-9 % Or sterols $$ (OTC) 9 % Bile acid sequest $$$ (gen) 10 % slo-niacin 500 bid $ (OTC) 5 % Factors to consider: tolerability, patient preference, cost, desired lipid changes, outcome evidence. 25
26 Ezetimibe (Zetia) Well tolerated, moves LDL well. Mixed results in imaging studies. Simvastatin / ezetimibe seemed to reduce events similar to equipotent statins in SHARP study. Await better event outcome data comparing statin alone to statin + ezetimibe (IMPROVE-IT). Brand cost about $500/yr (for ½ tab). Cost to pt depends on drug benefit. Plant Stanols / sterols 2 chews BID, $300/yr LDL 9% 1 chew BID, $150/yr, LDL 5%. 2 caps BID, $95/yr, LDL 9% NIH recommends 2 g daily. Dietary source is fat rich vegetables, fruits, and nuts Avg American gets 0.2 g daily Should not use in sitosterolemia - where pts get. xanthomas and CAD from inability to process plant stanols 26
27 Bile Acid Sequestrants (BAS) Lowers LDL about 23% (monotherapy) Favorable mono and combo outcome studies. Cholestyramine powder (Questran), 1 scoop BID: $300 Colestipol powder or tab bid: $500 Colesevalam (Welchol) bid: > $2000 / yr SE: Constipation, dyspepsia, can raise elevated TG, interferes with absorption of other meds (need to space timing). Slo-Niacin Slo-Niacin 500 mg bid LDL 5%, HDL 15% $ 51 / y Contraindicated with liver disease and active peptic ulcer disease. Glucose, uric acid Monotherapy studies benefit. Add on to statin no benefit in AIM-HIGH and HPS2-THRIVE Slo-Niacin 500 mg scored tabs ½ tab after dinner for 1 week, ½ tab bid for 1 week, then 1 tab po bid from then on. Time after dinner to decrease flushing. Flushing wanes over 2-3 months. 27
28 TG Therapy TG Guidance When statin indicated 1. If indication for statin, start statin. Statins are priority and can lower TG 20-30%. If TG are still > 200, 2. optimize potential contributing factors (hyperglycemia, excess alcohol, hypothyroid, obesity, medicines) and lifestyle interventions. If TG are still > 500, 3. Add/ or increase Omega-3 to 3-4 g daily and retest. If TG still > 500, then: consider add niacin consider intensify atorvastatin consider adding fenofibrate GFR > 30, use with sub-maximal dose statin 28
29 Both KP and Costco Omege 3 have 684 mg per softgel. (6 to 8 cents each) 5 caps / day = 3420 mg of Omega 3 for $110 / year. Diabetes: meds 4 CV reduction Screening: Hgb A1C > 6.5, Fasting Glucose > 126, 2 hr glu > ever. Metformin: Titrate up to 1000 mg bid right away, CV benefits. GFR use 500 bid. Statin: HEDIS measures performance in all DM. Guidelines rec: DM age > 40 or age < 40 with RF. Young DM with 80% lifetime CV risk. Aspirin 81 mg daily if 10 yr risk > 10% Men age with RF, all age Women age with RF. Lisinopril 20 mg for MA, HTN, or age > 55 with RF 29
30 Overview Lipids and CAD risk CVD is major killer and impacts morbidity Large statin benefit opportunity Treat high LDL (> 190) regardless of risk. Treat those at risk, regardless of LDL (>70) Optimizing Performance Identifying patients STAtin: Starts, Titrations, and Adherence Use tools to promote statins Safety / intolerance of statins Beyond statins Use tools and prevention to improve outcomes Use tools and prevention: integrated data / IT proactive care, CMSS, HC Artery graphic, patient relationship, clinical skill teamwork (care managers) Inexpensive generic atorvastatin, aspirin. To improve outcomes: Reduced CVD morbidity / mortality. Reduce costly CVD procedures, hospitalizations, and morbidity care. Better quality performance. Financial rewards for KP and for providers. 30
31 Question In JUPITER, rosuvastatin (Crestor) 20 mg (lowered LDL 50%) showed risk reduction of MI, and of combined endpoint of MI, stroke, revascularization, CV death of: A) MI 55% and combined endpoint 44%. B) MI 50% and combined endpoint 40%. C) MI 44% and combined endpoint 33%. 31
Implementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines
Summary Implementing new Dyslipidemia Guidelines Implementation of CV Risk and Dyslipidemia Guidelines Ronald D. Scott, MD Regional KPSC CVD Co-Lead Family Medicine and Lipidology, WLA ASCVD (Atherosclerotic
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More informationAchieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationQué factores de riesgo lipídicos debemos controlar? En qué medida?
Qué factores de riesgo lipídicos debemos controlar? En qué medida? Risk category High risk: CHD or CHD risk equivalents (10- year risk >20%) Moderately high risk: two or more risk factors (10-year risk
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationKavita Sharma, MD Diplomate, American Board of Clinical Lipidology
Lipid Management Kavita Sharma, MD Diplomate, American Board of Clinical Lipidology Clinical Director, Lipid Clinics Assistant Professor Division of Cardiovascular Medicine The Ohio State University Wexner
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationPresentation title. Better Health Care For Greater Cleveland Learning Collaborative March 5, Ron Adams, MD Regional Chief Internal Medicine
Better Health Care For Greater Cleveland Learning Collaborative March 5, 2010 Presentation title Ron Adams, MD Regional Chief Internal Medicine SUB TITLE HERE Prevent Heart Attacks and Strokes Every Day
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationDo Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus
Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationDYSLIPIDEMIA RECOMMENDATIONS
DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationLipids: Translating Studies into Practice. WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH
Lipids: Translating Studies into Practice WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH Discussants: Bob Gleeson, MD Assistant Professor of Medicine, General Internal Medicine Medical
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationTargeting Lipids Strategies for Patients with Cardiometabolic Risk
Targeting Lipids Strategies for Patients with Cardiometabolic Risk Faculty Disclosure David G. Carmouche, MD Director, Center for Cardiovascular Disease Prevention Baton Rouge Clinic ASH Specialist in
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationAcute Coronary Syndromes (ACS)
Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationIs it an era for statin for life?
Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for
More information